Evidence map›Paper›PMID 33674602›Full record

ArticleNature communications2021

Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma.

Stefan Antonowicz, Zsolt Bodai, Tom Wiggins, Sheraz R Markar, Piers R Boshier, Yan Mei Goh, Mina E Adam, Haonan Lu, Hiromi Kudo, Francesca Rosini and 9 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05600608 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome

TypeinterventionalSponsorAnuja MitraRan2022 to 2023Enrolled100ConditionsBreath Test, Oesophageal Cancer, Gastric Cancer, AugmentationArmsOral Stimulant Drink
NCT06453993 nacompletednot on this map

Temporal Variation in Exhaled Volatile Organic Compounds in Response to Therapeutic Intervention in Esophageal Cancer Patients

TypeinterventionalSponsorBenaroya Research InstituteRan2019 to 2023Enrolled46ConditionsEsophageal CancerArmsExhaled VOC breath test
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Breath Testing in the Surgical Setting: Applications, Challenges, and Future Perspectives.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes · 2023
    Review
  18. International journal of molecular sciences · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Stefan AntonowiczDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0002-9182-7753
Zsolt BodaiDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Tom WigginsDepartment of Surgery and Cancer, Imperial College London, London, UK.
Sheraz R MarkarDepartment of Surgery and Cancer, Imperial College London, London, UK.
Piers R BoshierDepartment of Surgery and Cancer, Imperial College London, London, UK.
Yan Mei GohDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0001-6964-0979
Mina E AdamDepartment of Surgery and Cancer, Imperial College London, London, UK.
Haonan LuDepartment of Surgery and Cancer, Imperial College London, London, UK.
Hiromi KudoDepartment of Surgery and Cancer, Imperial College London, London, UK.
Francesca RosiniCentre for Pathology, Imperial College London, London, UK.
Robert GoldinCentre for Pathology, Imperial College London, London, UK.ORCID 0000-0001-5184-4519
Daniela MoralliChromosome Dynamics Core, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0001-7977-8496
Catherine M GreenChromosome Dynamics Core, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Chris J PetersDepartment of Surgery and Cancer, Imperial College London, London, UK.
Nagy HabibDepartment of Surgery and Cancer, Imperial College London, London, UK.
Hani GabraDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0002-3322-4399
Rebecca C FitzgeraldMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0002-3434-3568
Zoltan TakatsDepartment of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
George B HannaDepartment of Surgery and Cancer, Imperial College London, London, UK. g.hanna@imperial.ac.uk.ORCID 0000-0003-2897-0140
Imperial College London · GBCentre for Human Genetics · GBUniversity of Cambridge · GB

Funding

Cancer Research UK 27981Cancer Research UK RG81771/84119Department of HealthMedical Research Council RG84369Wellcome TrustWellcome Trust 203141
6 · The paper itself

Abstract

Volatile aldehydes are enriched in esophageal adenocarcinoma (EAC) patients' breath and could improve early diagnosis, however the mechanisms of their production are unknown. Here, we show that weak aldehyde detoxification characterizes EAC, which is sufficient to cause endogenous aldehyde accumulation in vitro. Two aldehyde groups are significantly enriched in EAC biopsies and adjacent tissue: (i) short-chain alkanals, and (ii) medium-chain alkanals, including decanal. The short-chain alkanals form DNA-adducts, which demonstrates genotoxicity and confirms inadequate detoxification. Metformin, a putative aldehyde scavenger, reduces this toxicity. Tissue and breath concentrations of the medium-chain alkanal decanal are correlated, and increased decanal is linked to reduced ALDH3A2 expression, TP53 deletion, and adverse clinical features. Thus, we present a model for increased exhaled aldehydes based on endogenous accumulation from reduced detoxification, which also causes therapeutically actionable genotoxicity. These results support EAC early diagnosis trials using exhaled aldehyde analysis.

Indexed as

Biomarkers, TumorAdenocarcinomaAldehyde DehydrogenaseAldehyde OxidoreductasesAldehydesDNA AdductsDNA DamageEsophageal NeoplasmsEsophagusGenes, p53HumansMetforminAldehyde DehydrogenaseAldehyde OxidoreductasesAldehydesALDH3A1 protein, humanBiomarkers, TumorDNA Adductslong-chain-aldehyde dehydrogenaseMetformin

Identifiers

PMID33674602
PMCPMC7935981
OpenAlexW3135634171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.